Predict your next investment

iSTAR Medical company logo
HEALTHCARE | Medical Devices & Equipment / Surgical Devices
istarmed.com

See what CB Insights has to offer

Stage

Series C | Alive

Total Raised

$60.6M

Last Raised

$44.22M | 2 yrs ago

About iSTAR Medical

iSTAR Medical is a private, clinical-stage, medical technology company focused on the development of ophthalmic implants for glaucoma. iSTAR Medical's MIGS device, MINIjectTM, provides a safe, effective and sustainable solution to significantly reduce IOP by enhancing aqueous humor outflow from the anterior chamber to the supraciliary space.

iSTAR Medical Headquarter Location

Avenue Sabin, 6

Wavre, 1300,

Belgium

+32 (0)1077 16 54

Latest iSTAR Medical News

Belgian med-tech innovator iSTAR Medical secures €20 million European financing from the EIB

Nov 26, 2021

26 November 2021 ©iSTAR The EIB has signed a €20 million quasi-equity agreement with Belgian-based medical technology company iSTAR Medical SA iSTAR Medical’s innovative device MINIject ® is expected to set new standards in terms of ophthalmic implants for patients suffering glaucoma, the leading cause of irreversible blindness in the world. iSTAR Medical will use the funding to accelerate its R&D and Product Development activities specifically in clinical trials, regulatory matters and commercialisation The operation is carried out under the Pan-European Guarantee Fund (EGF) set up by the EIB with EU countries including Belgium The European Investment Bank (EIB) has signed a €20 million quasi-equity financing agreement with the Belgian medical technology company iSTAR Medical, based in Wavre, Belgium. The announcement and official signing took place at the headquarters of the company on 26 November, led by Kris Peeters, EIB Vice President and Michel Vanbrabant, CEO of iSTAR Medical, with the participation of Willy Borsus, Minister of Economy of Wallonia and (by videoconference) Michel Lussier, President of the Board of Directors of iSTAR Medical. iSTAR Medical is a medical technology company developing minimally-invasive implants for glaucoma surgery (MIGS). Glaucoma is the leading cause of irreversible blindness, affecting about 100 million people worldwide. iSTAR Medical’s innovative MIGS device, MINIject®, seeks to effectively treat more patients with MIGS. Data reported to date by iSTAR Medical across four trials in over 150 patients, consistently show that MINIject® demonstrates a balance of powerful and sustained intra-ocular pressure (IOP) reduction with a positive safety profile. MINIject® has been approved in Europe for open-angle glaucoma patients and the company is now entering a crucial phase of its international development as it rolls out MINIject® commercially in select regions across Europe. The EIB’s non-dilutive financing – a quasi-equity facility of €20 million – will support its R&D and Product Development activities specifically in further clinical trials, regulatory matters and the commercialisation phase. The financing is provided under the European Guarantee Fund (EGF), an initiative of the EIB Group in partnership with the EU Member States to support European companies in their development, which can be challenging in this pandemic period. EIB Vice-President Kris Peeters said at the signing event: “Supporting innovation and R&D in Europe is one of the EIB’s key goals, and med-techs such as iSTAR Medical are instrumental for Europe’s knowledge economy as they pursue innovation-intensive businesses and employ highly-qualified people. This is where the EIB comes in with tailored-made venture debt instruments.”  He added: “Above all, med-tech and other life science entrepreneurs bring ground-breaking benefits to patients. With MINIject®, its novel ophthalmic implant, iSTAR Medical sets new standards for treating patients suffering from glaucoma, a major cause of blindness, and we are proud to stand by them in their venture.” Michel Vanbrabant, CEO of iSTAR Medical, commented: “We are very pleased that we can now use the EIB facility as iSTAR Medical enters into a new and exciting phase following the recent European approval of our breakthrough device, MINIject®. We believe that MINIject® has great potential to improve the lives of glaucoma patients and our ambition is to bring this innovative technology to patients in Europe and beyond.” Willy Borsus, Vice-President of the Walloon Government, Minister of Economy said at the signing event: "I would like to congratulate iSTAR Medical on its deployment, its innovation and its commitment to the health sector. Such companies are essential for the economy of our Region, which is already at the forefront of medical technologies and wishes to remain so. I would like to extend my warmest thanks to the EIB for its ongoing support and investment in Wallonia's economic development". Background information: About the EIB In Belgium, with some €1.5 billion in 2020 for projects in various sectors ranging from healthcare, education, energy, water and industry to financing for small and medium businesses, the EIB Group made available support equal to 0.30% of Belgian GDP. ( Belgium and the EIB ) The European Guarantee Fund (EGF) was set up by the EIB Group with contributions from EU Member States (including Belgium) to support companies during the COVID-19 crisis. Using nearly €25 billion in guarantees, the EGF allows the EIB and the EIF to quickly make loans, guarantees, asset-backed securities, equity and other financial instruments available to mostly small and medium-sized enterprises, and mid-caps. The EGF is part of the European Union’s recovery package aiming to provide a total of €540 billion to boost those parts of the EU economy that have been hit the worst. About iSTAR Medical iSTAR Medical is committed to delivering breakthrough eye care solutions. Our most advanced product, MINIject®, is approved in Europe for the treatment of open-angle glaucoma – the leading cause of irreversible blindness [1] – and we are aiming to seek market approval in the US. MINIject’s unique tissue-integrating capabilities unlock a safer, and more effective option for patients. We are building an exceptional team and pipeline of best-in-class products such as MINIject® to establish new treatment paradigms in eye care conditions with the highest patient needs. For more information, please visit: www.istarmed.com About MINIject® MINIject ® is iSTAR Medical’s innovative MIGS device for patients with primary open-angle glaucoma. MINIject® combines the unique porous structure of its proprietary STAR material with the power offered by the supraciliary space. As a result, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications. Glaucoma is a progressive disease affecting over 100 million people globally, of which primary open-angle glaucoma is the most common form.1,2 IOP reduction, through medication or surgery, helps delay disease progression. [2] Medication is generally the first line treatment, but the progressive addition of multiple drops can burden patients with side effects, compliance challenges and costs.1,3 Invasive surgery can present risks with irreversible complications.1,3 MIGS is the most promising and fastest-growing glaucoma therapy due to its enhanced safety profile.1 MINIject® is potentially best-in-class for its promising long-term efficacy and safety. [1] Jonas JB, Aung T, Bourne RR et al. "Glaucoma". Lancet 2017; 390: 2083–93 [2] “European Glaucoma Society Terminology and Guidelines for Glaucoma”, 4th Edition: British Journal of Ophthalmology. 2017;101:1-195 https://bjo.bmj.com/content/101/5/73 Contact

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing iSTAR Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

iSTAR Medical is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

7,884 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

iSTAR Medical Patents

iSTAR Medical has filed 2 patents.

The 3 most popular patent topics include:

  • Diseases of the eye and adnexa
  • Eye surgery
  • Glaucoma
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/27/2012

1/6/2015

Diseases of the eye and adnexa, Ophthalmology, Glaucoma, Eye surgery, Sensors

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/27/2012

00/00/0000

Grant Date

1/6/2015

00/00/0000

Title

Subscribe to see more

Related Topics

Diseases of the eye and adnexa, Ophthalmology, Glaucoma, Eye surgery, Sensors

Subscribe to see more

Status

Grant

Subscribe to see more

iSTAR Medical Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

iSTAR Medical Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.